Benefit-risk assessment of mRNA COVID-19 vaccines in children aged 6 months to 4 years in the Omicron era.
Taito KitanoDaniel A SalmonMatthew Z DudleyDavid A ThompsonLilly EngineerPublished in: Journal of the Pediatric Infectious Diseases Society (2024)
The expected benefit of receiving the primary series of mRNA vaccines outweighed the risk among children ages 6 months to 4 years regardless of sex, presence of underlying medical conditions, presence of infection-induced immunity or type of mRNA vaccines. However, the continuous monitoring of the COVID-19 epidemiology as well as vaccine effectiveness and safety is important.